P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

B. Van Veggel; A. Van Der Wekken; S. Hashemi; R. Cornelissen; K. Monkhorst; D. Heideman; T. Radonic; E. Schuuring; E. Smit; J. De Langen

doi:10.1016/j.jtho.2018.08.1437

P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

B. Van Veggel, A. Van Der Wekken, S. Hashemi, R. Cornelissen, K. Monkhorst, D. Heideman, T. Radonic, E. Schuuring, E. Smit, J. De Langen

Research output: Contribution to journal › Article › Academic

Abstract

Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.

Original language	English
Pages (from-to)	S815
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	10
DOIs	https://doi.org/10.1016/j.jtho.2018.08.1437
Publication status	Published - 22 Oct 2018

Access to Document

10.1016/j.jtho.2018.08.1437

http://www.mendeley.com/research/p21342-osimertinib-treatment-patients-egfr-exon-20-insertion-positive-nonsmallcell-lung-cancer

Cite this

Van Veggel, B., Van Der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., ... De Langen, J. (2018). P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 13(10), S815. https://doi.org/10.1016/j.jtho.2018.08.1437

@article{ebbb046cd23046278c9e3090718351ec,

title = "P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer",

abstract = "Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.",

author = "{Van Veggel}, B. and {Van Der Wekken}, A. and S. Hashemi and R. Cornelissen and K. Monkhorst and D. Heideman and T. Radonic and E. Schuuring and E. Smit and {De Langen}, J.",

year = "2018",

month = "10",

day = "22",

doi = "10.1016/j.jtho.2018.08.1437",

language = "English",

volume = "13",

pages = "S815",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "10",

}

P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer. / Van Veggel, B.; Van Der Wekken, A.; Hashemi, S.; Cornelissen, R.; Monkhorst, K.; Heideman, D.; Radonic, T.; Schuuring, E.; Smit, E.; De Langen, J.

In: Journal of Thoracic Oncology, Vol. 13, No. 10, 22.10.2018, p. S815.

Research output: Contribution to journal › Article › Academic

TY - JOUR

T1 - P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

AU - Van Veggel, B.

AU - Van Der Wekken, A.

AU - Hashemi, S.

AU - Cornelissen, R.

AU - Monkhorst, K.

AU - Heideman, D.

AU - Radonic, T.

AU - Schuuring, E.

AU - Smit, E.

AU - De Langen, J.

PY - 2018/10/22

Y1 - 2018/10/22

N2 - Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.

AB - Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.

UR - http://www.mendeley.com/research/p21342-osimertinib-treatment-patients-egfr-exon-20-insertion-positive-nonsmallcell-lung-cancer

U2 - 10.1016/j.jtho.2018.08.1437

DO - 10.1016/j.jtho.2018.08.1437

M3 - Article

VL - 13

SP - S815

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 10

ER -